Published text:

Atlas-based segmentation
Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk

Jamie A. Dean a,*, Liam C. Welsh b, Dualta McQuaid a, Kee H. Wong b, Aleksandar Aleksic b, Emma Dunne b, Mohammad R. Islam b, Anushka Patel b, Priyanka Patel b, Imran Petkar b, Iain Phillips b, Jackie Sham b, Kate L. Newbold b,c, Shreerang A. Bhide b,c, Kevin J. Harrington b,c, Sarah L. Gulliford a, Christopher M. Nutting b,c

a Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust; b The Royal Marsden NHS Foundation Trust; and c Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK

Article info
Article history:
Received 27 November 2015
Received in revised form 5 February 2016
Accepted 9 February 2016
Available online 9 March 2016

Keywords:
Atlas-based segmentation
Contouring
Delineation
OAR
Oral mucosa
Oral cavity

Abstract
Background and purpose: Current oral mucositis normal tissue complication probability models, based on the dose distribution to the oral cavity volume, have suboptimal predictive power. Improving the delineation of the oral mucosa is likely to improve these models, but is resource intensive. We developed and evaluated fully-automated atlas-based segmentation (ABS) of a novel delineation technique for the oral mucosal surfaces.

Material and methods: An atlas of mucosal surface contours (MSC) consisting of 46 patients was developed. It was applied to an independent test cohort of 10 patients for whom manual segmentation of MSC structures, by three different clinicians, and conventional outlining of oral cavity contours (OCC), by an additional clinician, were also performed. Geometric comparisons were made using the dice similarity coefficient (DSC), validation index (VI) and Hausdorff distance (HD). Dosimetric comparisons were carried out using dose-volume histograms.

Results: The median difference, in the DSC and HD, between automated-manual comparisons and manual-manual comparisons were small and non-significant (−0.024; p = 0.33 and −0.5; p = 0.88, respectively). The median VI was 0.086. The maximum normalised volume difference between automated and manual MSC structures across all of the dose levels, averaged over the test cohort, was 8%. This difference reached approximately 28% when comparing automated MSC and OCC structures.

Conclusions: Fully-automated ABS of MSC is suitable for use in radiotherapy dose–response modelling.

* Corresponding author at: Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK.
E-mail address: jamie.dean@icr.ac.uk (J.A. Dean).

Oral mucositis is a common and important toxicity of head and neck radiotherapy. It impacts on patients’ quality of life [1], potentially causing pain, dysphagia [2–4] and consequential “late” effects [5–8]. It is frequently the limiting toxicity in dose-escalation and accelerated fractionation regimens that aim to improve tumour control [9–11]. Currently, normal tissue complication probability models have limited predictive performance and are not routinely used to aid clinical decision-making. Additionally, further evidence is required to find an optimal strategy for dose-sparing of the oral mucosa to reduce the incidence of severe toxicity.

In an attempt to improve the performance of oral mucositis normal tissue complication probability (NTCP) models developed by our group [12], we devised a novel contouring approach, which characterises the dose delivered to the mucosal surfaces of the oral cavity (MSC), including the buccal mucosa, mucosa of the lips and mucosa of the oral tongue [13]. We believe that this offers an improvement over the previously used oral cavity contours (OCC) volume (equivalent to the “extended oral cavity” structure in international consensus guidelines detailed in [14]), which predominantly describes the dose distribution to the musculature of the tongue and floor of mouth and does not incorporate the dose delivered to the buccal mucosa or mucosa of the lips. Differences in delineation guidelines have been shown to lead to differences in reported dose metrics and corresponding NTCP estimates [15]. To test whether our novel contouring approach improves NTCP modelling of oral mucositis, we must apply it to a large cohort of patients for whom we have mucositis outcome data.

http://dx.doi.org/10.1016/j.radonc.2016.02.022
0167-8140/© 2016 The Authors. Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Organ-at-risk (OAR) segmentation is highly time- and resource-intensive. This has motivated the development and evaluation of algorithms for automatic OAR segmentation [16,17]. The burden of OAR contouring can limit the feasibility of performing dose-response studies that make use of a large enough patient cohort (of the order of hundreds or thousands of patients) to enable strong statistical inference. This is especially true when the OAR of interest is not contoured as part of routine clinical practice and is challenging to delineate. This is certainly the case for MSC due to the relatively poor image contrast on planning CT scans and its complex shape. Being able to automate the MSC segmentation process would thus be of great benefit to oral mucositis dose-response modelling. It could also be valuable for use in treatment plan optimization and assessment.

The aim of this study was to assess the performance of fully-automated (with no post hoc editing) atlas-based segmentation (ABS) of the MSC, in terms of geometry and dosimetry, in order to ascertain its suitability for use in dose-response modelling. The primary endpoint of our study was defined, prior to commencing the work, by pre hoc acceptability criteria, as follows: (i) if the geometric differences between the ABS-generated MSC (MSCABS) and manually delineated MSC (MSCmanual) did not exceed the inter-clinician variability and (ii) if the dosimetric differences between MSCABS and MSCmanual were smaller than those between the MSCABS and OCC (which is the current international standard) structures, then the MSCABS approach would be deemed suitable for dose-response modelling.

Materials and methods

Atlas construction

An MSC atlas of 46 patients, treated in the phase III trial of parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer (PARSPORT) (CRUK/03/005 [18]), was generated from MSCmanual structures delineated on contrast-enhanced computed tomography (CT) scans by six clinical oncologists (L.W., E.D., R.I., P.P., I.Ph. and J.S.) using the RayStation, research version 4.6.100.12 treatment planning system (RaySearch Laboratories AB, Stockholm, Sweden). We have previously described the structure and contouring technique in detail [13]. Briefly, it includes the “buccal mucosa, buccal gingiva, gingiva proper, lingual gingiva, lingual frenulum, alveolar mucosa, labial mucosa, labial gingiva, labial frenulum, mucosal surface of the floor of mouth, mucosal surface of the tongue anterior to the terminal sulcus, and the mucosal surface of the hard palate”. As described previously, the structures added to the atlas were the lines representing the positions of mucosal surfaces rather than the expanded 3 mm thick wall structure, as previously described [13].

Manual segmentation by multiple clinicians

MSCmanual contouring was performed for the same 10 patients by each of three clinical oncologists (A.A., A.P. and I.Pe.). When performing the contouring, the clinicians were blinded to the MSCmanual structures contoured by the other clinicians and the MSCABS structures. The contoured mucosal surface lines were expanded to a 3 mm thick wall as previously described [13]. The clinical oncologists received training in the contouring technique prior to commencing the study. Manual OCC segmentation was performed for the same 10 patients by a clinical oncologist (K.W.) to enable dosimetric comparison between the new MSCABS structure and the conventionally used OCC structure. The OCC structure is based on international consensus guidelines and is equivalent to the “extended oral cavity” OAR described in [14].

Comparison of automated and manual segmentation

In-house software was written to extract the structure coordinates from RayStation and perform comparisons of the different structures using the Python programming language version 2.7.9 [19] and the NumPy version 1.9.2 [20], SciPy version 0.16.0 [21], Matplotlib version 1.4.3 [22] and PyDicom version 0.9.9 [23] modules.

A geometric comparison was performed using the dice similarity coefficient (DSC) [24], validation index (VI) [15] and Hausdorff distance (HD) [25]. The DSC describes the amount of agreement between two volumes, V and S, and is given by

\[
\text{DSC} = \frac{|V \cap S|}{|V| + |S| - |V \cap S|}
\]

The VI is a recently designed measure, for geometric comparison of automated and multiple manually contoured structures, that attempts to account for uncertainties in the manual contouring [26].

\[
\text{VI} = \frac{1}{N} \sum_{k=1}^{N} \left( \frac{\sum_{j=1}^{N} \left| V_k \cap V_j \right|}{\sum_{j=1}^{N} \left| V_j \right|} \right)^k \left( \frac{1}{N} \sum_{j=1}^{N} \left| V_k \cap V_j \right| \right)
\]

where \( V_k \) is the volume of overlap between \( k \) experts out of a total of \( N \) experts, \( S \) is the whole automated segmentation and \( x \) is a control parameter (allowing for the weighting term (first bracket in Eq. (2)) to be changed to meet specific radiotherapy treatment planning requirements in terms of how conservative the segmentation should be), which was set to 1. When \( x = 1 \) the first bracket in Eq. (2) represents the normalised frequency at which the different proportions of agreeing clinicians for a volume (second bracket in Eq. (2)) occur. VI is 0 if the ABS has no overlap with the manual structures and 1 if the ABS and all manual structures perfectly overlap. The HD describes the maximum of all of the distances from each point in one structure to the closest point in the other structure.

The means of the DSC and HD values for the pairwise comparison between MSCABS and each of the three MSCmanual structures (DSCpw,ABS and HDpw,ABS) were calculated for each patient. The means of the DSC and HD values for the pairwise comparisons between the different manually contoured structures (DSCpw,man and HDpw,man) were also calculated for each patient and these value subtracted from the DSCpw,ABS and HDpw,ABS values for comparison (DSCpw,diff and HDpw,diff). A two-tailed Wilcoxon signed-rank test was used to test for statistical significance.

A dosimetric comparison was carried out using fractional dose–volume histograms (DVHs). The differences in the normalised volumes receiving each dose level between the MSCABS and each
of the OCC and MSC\textsubscript{manual} structures were measured and compared.

**Results**

In all cases the ABS was able to segment the MSC without any gross errors. Fig. 1 shows an example of the ABS and manual MSC contours for patient 4. The greatest variation between the structures is in the position of the posterior border, the lateral extents of the buccal mucosa and the inferior extent of the mucosa where the lateral tongue base meets the mucosa overlying the floor of mouth. This was representative of the whole 10-patient cohort. The ABS performed poorest, as assessed by DSC, HD and VI, for patient 2. In this case the MSC\textsubscript{ABS} structure extended too far

![Fig. 1. Example (patient 4) of the fully-automated ABS-generated MSC structure (top and bottom; green), the manually delineated OCC structure (top; red) and three different manually delineated MSC structures (bottom; pink, purple and coral). For each set of 3 images (top and bottom) the left, top right and bottom right images are coronal, sagittal and axial views, respectively.](image)

<table>
<thead>
<tr>
<th>Patient</th>
<th>VI</th>
<th>DSC\textsubscript{pre,ABS}</th>
<th>DSC\textsubscript{pre,man}</th>
<th>DSC\textsubscript{pre,diff}</th>
<th>HD\textsubscript{pre,ABS} (mm)</th>
<th>HD\textsubscript{pre,man} (mm)</th>
<th>HD\textsubscript{pre,diff} (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.033</td>
<td>0.070</td>
<td>0.134</td>
<td>-0.064</td>
<td>21.0</td>
<td>16.1</td>
<td>4.9</td>
</tr>
<tr>
<td>2</td>
<td>0.025</td>
<td>0.062</td>
<td>0.269</td>
<td>-0.207</td>
<td>21.3</td>
<td>14.8</td>
<td>6.5</td>
</tr>
<tr>
<td>3</td>
<td>0.089</td>
<td>0.210</td>
<td>0.159</td>
<td>0.052</td>
<td>13.3</td>
<td>14.4</td>
<td>-1.1</td>
</tr>
<tr>
<td>4</td>
<td>0.152</td>
<td>0.327</td>
<td>0.349</td>
<td>-0.022</td>
<td>13.7</td>
<td>13.6</td>
<td>0.1</td>
</tr>
<tr>
<td>5</td>
<td>0.115</td>
<td>0.270</td>
<td>0.352</td>
<td>-0.082</td>
<td>11.5</td>
<td>15.4</td>
<td>-3.9</td>
</tr>
<tr>
<td>6</td>
<td>0.124</td>
<td>0.283</td>
<td>0.309</td>
<td>-0.026</td>
<td>13.1</td>
<td>16.1</td>
<td>-3.0</td>
</tr>
<tr>
<td>7</td>
<td>0.063</td>
<td>0.162</td>
<td>0.111</td>
<td>0.051</td>
<td>12.5</td>
<td>17.2</td>
<td>-4.7</td>
</tr>
<tr>
<td>8</td>
<td>0.056</td>
<td>0.137</td>
<td>0.098</td>
<td>0.040</td>
<td>17.8</td>
<td>21.0</td>
<td>-3.2</td>
</tr>
<tr>
<td>9</td>
<td>0.105</td>
<td>0.243</td>
<td>0.272</td>
<td>-0.029</td>
<td>17.4</td>
<td>14.8</td>
<td>2.6</td>
</tr>
<tr>
<td>10</td>
<td>0.082</td>
<td>0.185</td>
<td>0.204</td>
<td>-0.018</td>
<td>16.7</td>
<td>13.4</td>
<td>3.3</td>
</tr>
<tr>
<td>Median</td>
<td>0.086</td>
<td>0.198</td>
<td>0.236</td>
<td>-0.024</td>
<td>15.2</td>
<td>15.1</td>
<td>-0.5</td>
</tr>
</tbody>
</table>

VI = validation index; DSC\textsubscript{pre,ABS} = mean of the dice similarity coefficients for pairwise comparisons between the automatically segmented structure and each of the three manually delineated structures; DSC\textsubscript{pre,man} = mean of the dice similarity coefficients for pairwise comparisons between the three different manually delineated structures (3 different combinations of pairwise comparisons); DSC\textsubscript{pre,diff} = DSC\textsubscript{pre,ABS} minus DSC\textsubscript{pre,man}; HD\textsubscript{pre,ABS} = mean of the Hausdorff distances for pairwise comparisons between the automatically segmented structure and each of the three manually delineated structures; HD\textsubscript{pre,man} = mean of the Hausdorff distances for pairwise comparisons between the three different manually delineated structures (3 different combinations of pairwise comparisons); HD\textsubscript{pre,diff} = HD\textsubscript{pre,ABS} minus HD\textsubscript{pre,man}. \(p\)-value for two-tailed Wilcoxon signed-rank test.
inferiorly beyond where the lateral tongue border meets the floor of mouth.

The geometric comparisons are described in Table 1. The DSC increases with increasing overlap between structures. The HD decreases with increasing proximity of structures. The median values of DSC_{pw,diff} and HD_{pw,diff} were small in magnitude and not close to statistically significant at the \( p = 0.05 \) level. This indicates that the geometric differences between the MSC_{ABS} and MSC_{manual} structures did not exceed the geometric differences between MSC_{manual} structures delineated by different clinicians. Therefore, our \textit{pre hoc} criterion (i) was met. The VI values were substantially lower than the DSC_{pw,ABS} values. This is because DSC_{pw,ABS} generally overestimates the agreement between ABS and manual structures due to not incorporating the amount of agreement between multiple clinician-delineated structures.

Fig. 2 summarises the DVHs for the 10-patient cohort using the different structures. Fig. 3 shows the pairwise differences in the DVHs between the different structures for each of the 10 patients. The median MSC_{ABS} DVH falls within the centre of the median MSC_{manual} DVH range across the three clinicians (A.A., A.P., I.Pe.). The maximum normalised volume differences at any dose level were, on average across the cohort, within 8%. The dose distributions extracted using the OCC structure characterise larger volumes receiving low and intermediate doses than any of the automated or manual MSC structures. The maximum normalised volume difference between the MSC_{ABS} and OCC structures, average across the cohort, was 28%. This indicates that the dosimetric differences between the MSC_{ABS} and MSC_{manual} structures were small and substantially smaller than the differences between the MSC_{ABS} and OCC structures. Therefore, our \textit{pre hoc} criterion (ii) and, hence, the primary endpoint of our study was met. Moreover, the MSC_{ABS} (and MSC_{manual}) structures capture information on the dose delivered to the buccal mucosa, which is not captured by the OCC structure (Fig. 1).

**Discussion**

The results of the geometric comparison between the MSC_{ABS} and MSC_{manual} structures indicate that the difference between fully-automated and manual segmentation of the MSC structure is within the inter-clinician variability of the manual delineation. The same is true of the dosimetric comparison between the MSC_{ABS} and MSC_{manual} structures. Furthermore, the dosimetric comparison demonstrates that the DVHs for the MSC_{ABS} structure are more similar to the “gold standard” MSC_{manual} Structures than the OCC structure that was previously employed for dose–response modelling. Based on our \textit{pre hoc} criteria, the primary endpoint of our study was met. We, therefore, suggest that the MSC_{ABS} structure is suitable for use for oral mucosa dose–response modelling.

The DSC and VI values are low for the comparison of the MSC_{ABS} and MSC_{manual} structures and the inter-clinician comparisons. This is a result of the nature of the morphology of the structure being wall-like. DSC is highly sensitive to the volume of the structure. The same is also true of the VI metric. This can be illustrated using a “toy” example. Two cubes, of dimension 10 units, diagonally displaced, by 1 unit in each dimension, have a DSC of 0.729. Two hollow cubes, of dimension 10 units and thickness 1 unit, with the same displacement, have a substantially lower DSC of 0.098. This
makes it challenging to determine whether an automated contouring approach is suitable for clinical use solely using a threshold value of the DSC or VI. The current “gold-standard” for OAR contouring is manual delineation by a trained expert [27]. However, variability exists between delineations performed by different experts, even when following the same guidelines [28]. Therefore, there exists a rationale for deciding whether an automated approach is fit for clinical use based on whether or not it falls within or outside the variability of clinical oncologists who would perform the manual delineation for clinical use. Several studies evaluating the performance of automated structure segmentation simply use the DSC magnitude value to assess suitability for clinical use. We suggest that our method, in which we compared the differences in automated and manually segmented structures to inter-clinician variability in the manual segmentation, is, at least, equally valid.

The median HD\(_{pw,diff}\) value provides further indication that the automated segmentation fell within the range of the inter-clinician variability in manual segmentation. Unlike the DSC and VI values, the HD values are not sensitive to the volumes of the structures. Using the same “toy” example, the two displaced cubes have a HD of 1.73 units and the two displaced hollow cubes also have a HD of 1.73 units. This suggests that HD is a more suitable metric for assessing the similarity between structure segmentations than DSC for small volume or wall-like structures.

The dosimetric comparison data (Figs. 2 and 3) indicate that the MSC\(_{cav}\) structure provides a dose distribution to the oral mucosal surfaces that is closer to the MSC\(_{manual}\) Structures than the previously used OCC structure. This provides further rationale for using the MSC\(_{ABS}\) structure, rather than the OCC structure, for dose-response modelling. Many other studies evaluating the performance of automated structure segmentation consider only geometric indices and do not directly measure the effects of geometric differences on the dose distribution to the segmented structure. We suggest that dosimetric comparisons can also provide useful, and often more relevant, information in performing such evaluations, particularly for small or wall-like structures.

A potential limitation of our study is the use of six different clinicians to perform the delineation of the structures included in the atlas. This may have led to increased variability in the atlas MSC structures compared with what might have been produced had a single clinician performed all of the delineations. The fact that the VI values were substantially lower than the DSC\(_{pw,ABS}\) values indicates that there was uncertainty in the manual delineation of the MSC structure. This is likely due to the relatively poor CT image contrast and complex shape of the structure. We trained the clinicians performing the delineation and independently reviewed and edited the contours in an attempt to minimise the effects of inter-clinician variability in the atlas. However, some variation inevitably remained. This could explain the poorer performance of the ABS for patient 2. The MSC for the atlas patient selected in the initial rigid registration comparison step of the ABS may also have extended too far inferiorly. Multi-atlas-based segmentation (using information from all of the available patients, rather than just the one that is the closest match, to perform the automated segmentation) might improve the robustness of the automated segmentation (at the expense of computational time) [29], but we were unable to assess this, as RayStation does not currently include a multi-atlas segmentation algorithm. We would expect this approach to reduce the sensitivity of the ABS to the atlas patient selected and, therefore, improve the ABS performance for patient 2.

Moreover, it should be noted that the patients included in this study did not have tumours of the oral cavity. Therefore, based on our data, we cannot guarantee that the performance of the automated or manual segmentation of the MSC for patients with oral cavity tumours will match that reported in this study. The cohort that we intend to apply this technique to for NTCP modelling does not contain patients with oral cavity tumours. Including patients for whom the MSC include tumour could confound investigations of the dose–response relationship of normal oral mucosa. Furthermore, it is unlikely that the MSC could be spared if it overlapped with the planning target volume, reducing the utility of segmenting the MSC.

When applying the MSC structure to NTCP modelling, it is important to consider that scoring of oral mucositis also takes into account mucosal surfaces not included as part of the MSC structure, particularly the oropharynx. For this reason, when applying the MSC approach to NTCP modelling of oral mucositis, we recommend that the pharyngeal mucosa also be considered as an OAR.

In conclusion, we performed a thorough geometric and dosimetric assessment of fully-automated ABS of the novel MSC OAR structure and demonstrated that it is suitable for use in radiotherapy dose–response studies. This represents the first evaluation of a method to fully segment the oral mucosal surfaces automatically. In the future, we aim to apply this contouring approach to a cohort of patients from six head and neck radiotherapy trials and establish whether it improves the predictive performance of NTCP modelling of severe acute mucositis.

Conflict of interest statement

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Acknowledgments

This work was supported by the Engineering and Physical Sciences Research Council, Cancer Research UK Programme Grant A13407 and NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and ICR. The PARSORT and COSTAR trials were supported by Cancer Research UK (trial reference numbers CRUK/03/005 and CRUK/08/004). We wish to thank Hannah Eyles, Emma Wells, Dr Emma Hall at The Institute of Cancer Research Clinical Trials and Statistics Unit, Dr Cornelis Kamerling, Dr Alex Dunlop, Dr Simeon Nill and Prof Uwe Oelfke for general support.

References


